Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Implementing a validation program in a cord blood bank

B O'Neil1

  • 1Viacord, Inc., Boston, MA 02116, USA.

Journal of Hematotherapy
|April 1, 1996
PubMed
Summary

Cord blood banking regulation is evolving, likely becoming a licensed blood product requiring preapproval inspections. Establishing a scientifically sound validation program is critical for regulatory approval.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Coccidioidomycosis in non-endemic areas: a case series.

Respiratory medicine·2001
Same author

Brucellosis eradication scheme successfully completed.

The New Zealand medical journal·1995
Same author

T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy·1994
Same author

Clinical and pathological findings in feline immunodeficiency virus experimental infection.

Veterinary immunology and immunopathology·1992
Same author

Lymphosarcoma in experimentally induced feline immunodeficiency virus infection [corrected].

The Veterinary record·1992
Same author

The myelotoxicity of carboplatin is influenced by the time of its administration.

Hematological oncology·1990

Area of Science:

  • Biologics Regulation
  • Hematology
  • Regulatory Science

Background:

  • The regulatory landscape for cord blood banking has been evolving since 1993.
  • Recent developments indicate an accelerated pace in establishing regulatory policy.

Purpose of the Study:

  • To discuss the evolving regulatory climate for cord blood banking.
  • To outline the critical elements of validation for regulatory approval.

Main Methods:

  • Analysis of the current regulatory framework for human somatic cell therapy.
  • Discussion of the anticipated regulatory pathway for cord blood banking as a blood product.
  • Identification of key validation program components.

Main Results:

  • Cord blood banking is expected to be regulated as a new blood product by the Center for Biologics Evaluation and Research (CBER).
  • This regulation will involve licensing and preapproval inspections.
  • Validation is identified as a crucial component of the approval process.

Conclusions:

  • The regulatory oversight for cord blood banking is set to intensify.
  • Implementing a robust validation program is essential for compliance and market entry.
  • Understanding these regulatory shifts is vital for stakeholders in cord blood banking.

Related Experiment Videos